XENE
Xenon Pharmaceuticals Inc
36.90$
-2.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | – | – | 100.0% | |
| – | 51.2% | 22.7% | 20.8% | 17.7% | 61.8% | 8,222.8% | – | 568.8% | 157.1% | 409.3% | 1,121.1% | – | – | 33.9% | |
| 100.0% | 48.8% | 77.3% | 79.2% | 100.0% | 38.2% | -8,122.8% | – | 100.0% | 100.0% | 100.0% | 100.0% | – | – | 66.1% | |
| 177.8% | 73.1% | 45.0% | 41.5% | 97.3% | 1,099.7% | 8,222.8% | – | 568.8% | 157.1% | 409.3% | 1,121.1% | – | – | 4,012.5% | |
| 97.3% | 49.0% | 19.5% | 19.4% | 62.8% | 376.7% | 2,351.4% | – | 158.2% | 40.2% | 119.1% | 347.8% | – | – | 1,061.8% | |
| 275.1% | 122.0% | 64.5% | 60.9% | 160.1% | 1,476.4% | 10,574.3% | – | 727.0% | 197.3% | 528.4% | 1,468.9% | – | – | 5,040.4% | |
| -175.1% | -22.0% | 35.5% | 39.1% | -60.1% | -1,376.4% | -10,474.3% | – | -627.0% | -97.3% | -428.4% | -1,368.9% | – | – | -4,974.3% | |
| 1.3% | 0.6% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | – | 21.0% | 1.5% | 5.5% | 58.4% | – | – | – | |
| -173.3% | -30.1% | 44.0% | 45.9% | -101.1% | -1,275.5% | -9,872.7% | – | -609.4% | -90.4% | -427.9% | -1,327.7% | – | – | -4,598.6% | |
| 1.3% | 0.6% | 0.2% | 0.0% | -6.7% | -100.9% | -601.6% | – | -0.3% | -0.8% | 0.0% | 1.3% | – | – | 13.5% | |
| -173.3% | -30.1% | 44.0% | 45.9% | -101.1% | -1,275.5% | -9,872.7% | – | -609.1% | -89.7% | -427.8% | -1,328.9% | – | – | -4,612.1% | |
| -155.7% | -23.9% | 38.1% | 41.7% | -53.4% | -1,328.5% | -9,664.0% | – | -582.1% | -95.3% | -423.5% | -1,351.7% | – | – | -4,564.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.